IPM Take
This is not only another myeloma approval. It is a live test of how far regulators, clinicians and payers are willing to go with minimal residual disease as an early marker of benefit. For patients, earlier access matters. For systems, the question is whether accelerated approval can move fast without letting confirmatory evidence move slowly.
Executive Summary
The FDA granted accelerated approval to iberdomide, marketed as Zenbexus, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. In EXCALIBER-RRMM, the major efficacy outcome was MRD-negative complete response at any time. The MRD-negative complete response rate was 41% with iberdomide plus daratumumab and dexamethasone versus 21% with daratumumab, bortezomib and dexamethasone. The label includes a boxed warning for embryo-fetal toxicity and serious venous and arterial thromboembolism, and the drug is available only through a REMS restricted distribution programme. (U.S. Food and Drug Administration)
Why it matters
- Patients / advocates: Earlier access to a new class-based option may matter for patients whose disease has already escaped first-line control.
- Clinicians: The approval moves CELMoD-based treatment into an earlier relapsed setting and adds another sequencing decision to myeloma care.
- Regulators: This is another high-stakes accelerated approval built around an early disease-control endpoint.
- Payers / HTA bodies: The value debate will need to weigh MRD-negative complete response, toxicity, treatment duration, REMS burden and future confirmatory results.
Myeloma has become one of oncology’s most crowded innovation spaces. That is good news for patients. It is also making the evidence debate harder.
The FDA’s accelerated approval of iberdomide with daratumumab and dexamethasone brings a CELMoD regimen into adults with multiple myeloma after at least one prior line of therapy that included a proteasome inhibitor and an immunomodulatory agent. This is not a late, last-chance niche. It is a relatively early relapsed setting, where treatment sequencing already has too many moving parts.
The trial result is clear enough to justify attention. In EXCALIBER-RRMM, MRD-negative complete response at any time was 41% in the iberdomide arm versus 21% in the comparator arm. That is a meaningful difference.
But MRD is also the politics of this story.
Accelerated approval is designed to move medicines faster when patients need options. That purpose is defensible. The danger comes when early endpoints become a substitute for long-term accountability. Myeloma patients need faster access, but they also need to know whether deeper MRD responses translate into longer progression-free survival, better overall survival, tolerable treatment, and enough quality of life to justify the burden.
The safety issues are not small. The prescribing information includes warnings for embryo-fetal toxicity, thromboembolism, neutropenia, infections and secondary primary malignancies. The REMS programme is not a footnote; it is part of the access pathway. A patient does not receive this medicine in a vacuum. They receive it through a system that must monitor, counsel, prevent harm and manage logistics.
This is where the myeloma field needs discipline. Innovation is moving quickly. Evidence confirmation must move quickly too.
